Pateclizumab

N/A

Report date: 2022/07/04 19:38:02

Base Information

Drug NamePateclizumab
Drug Alias NamepateclizumabumAnti-LT alphapateclizumabMLTA-3698ARG-7416 +[7] 
ClassificationBiologics > Protein drugs > Immunoglobulin > Antibody > Monoclonal antibody > Monoclonal antibody humanized
Mechanisms of ActionTumor necrosis factor β inhibitors
TargetsTumor necrosis factor β
Therapy Area/IndicationsArthritis, Rheumatoid
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryBulgariaUnited StatesPoland +[10] 
CombinationsNo
Global Highest StatusPending (Phase 2 Clinical)
Highest Status in ChinaN/A
Originator CompaniesGenentech Inc
China Registration ClassN/A

Develop Information

Active CompaniesN/A
Inactive CompaniesGenentech Inc
Active IndicationsN/A
Inactive IndicationsArthritis, Rheumatoid

Other Information

ATC CodeN/A
Related LinksWikipediaKEGG